BCRX BioCryst Pharmaceuticals, Inc. - Common Stock

NASDAQ · Biotechnology · Voir sur SEC EDGAR ↗
$9,88
Prix · Aoû 18, 2026
Données fondamentales au Aoû 5, 2026
Fourchette 52 semaines
$6–$11
74% of range
Note des analystes
BUY
17 analysts
Objectif de cours
$21
+111% upside
P/E (TTM)
9.7
ROE
-97.6%
Marge nette
30.2%

À propos de BioCryst Pharmaceuticals, Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.

Lire la suite

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.

History

The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.

In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.

Pipeline

BioCryst’s core development programs include:

Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).

FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.

Berotralstat has a PDUFA date for FDA approval on December 3, 2020.

On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.

BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.

FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).

Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.

Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.

In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.

BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.

In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.

In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.

In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.

Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗

Wikidata ↗

BCRX Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines

Prix
$9.88
Capitalisation Boursière
$2.51B
P/E (TTM)
9.7
BPA (TTM)
$1.21
Revenus (TTM)
$875M
Rendement div.
—
ROE
-97.6%
Dette/Capitaux propres
0.0
Fourchette 52 semaines
$6 – $11

BCRX Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue

Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA

Revenus et bénéfice net $875M
10-point trend, +3219.7%
2016-12-31 → 2025-12-31
BPA $1.21
6-point trend, +211.0%
2020-12-31 → 2025-12-31
Flux de trésorerie libre $345M
9-point trend, +687.4%
2016-12-31 → 2025-12-31
Marges 30.2%

Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?

Métrique
Tendance sur 5 ans
BCRX
Médiane des pairs
P/E (TTM)
5-point trend, +147.9%
9.7
97.6
P/S (TTM)
5-point trend, -88.3%
2.9
7.7
P/B
5-point trend, +41.6%
-21.1
8.0
EV / EBITDA
5-point trend, +132.8%
6.5
—
Price / FCF (Cours / FCF)
5-point trend, +127.3%
7.3
—

Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC

Métrique
Tendance sur 5 ans
BCRX
Médiane des pairs
Operating Margin (Marge d'exploitation)
5-point trend, +134.5%
39.0%
—
Net Profit Margin (Marge nette)
5-point trend, +125.8%
30.2%
-51.7%
ROA
5-point trend, +231.7%
52.5%
-44.2%
ROE
5-point trend, -167.3%
-97.6%
-63.5%
ROIC
5-point trend, +54.3%
-282.4%
—

Santé financière Dette, liquidité, solvabilité — solidité du bilan

Métrique
Tendance sur 5 ans
BCRX
Médiane des pairs
Debt / Equity (Dette / Capitaux propres)
5-point trend, +100.0%
0.0
18.7
Current Ratio (Ratio de liquidité)
5-point trend, -62.2%
2.1
4.9
Quick Ratio (Ratio de liquidité réduite)
5-point trend, -62.2%
1.9
—

Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans

Métrique
Tendance sur 5 ans
BCRX
Médiane des pairs
Revenue YoY (Chiffre d'affaires YoY)
5-point trend, +456.6%
94.1%
—
Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans)
5-point trend, +456.6%
47.8%
—
Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans)
5-point trend, +456.6%
117.9%
—

Indicateurs par action BPA, valeur comptable par action, flux de trésorerie par action, dividende par action

Métrique
Tendance sur 5 ans
BCRX
Médiane des pairs
EPS (Diluted) (BPA (Dilué))
5-point trend, +217.5%
$1.21
—

Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances

Métrique
Tendance sur 5 ans
BCRX
Médiane des pairs

BCRX Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse

ACHAT 17 analystes
  • Achat fort 5 29,4%
  • Achat 10 58,8%
  • Conserver 2 11,8%
  • Vente 0 0,0%
  • Vente forte 0 0,0%

Objectif de cours à 12 mois

11 analystes · 2026-08-17
Objectif médian $17.00 +72,1%
Objectif moyen $20.82 +110,7%

Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats

Surprise Moyenne
0.02%
Période EPS Actual BPA est. Surprise
30 juin 2026 $0.30 $0.12 0.18%
31 mars 2026 $-0.09 $0.05 -0.14%
31 décembre 2025 $0.01 $0.04 -0.03%
30 septembre 2025 $0.06 $0.04 0.02%
30 juin 2025 $0.04 $0.01 0.03%
31 mars 2025 $0.00 $-0.07 0.07%

Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur

Ticker Capitalisation Boursière P/E Revenus Année/Année Marge Nette ROE Marge Brute
BCRX $1.66B 6.4 94.1% 30.2% -97.6% —
BEAM $2.82B -34.2 120.0% -57.2% -7.0% —
KOD $1.73B -6.5 — — -202.0% —
SLS $577M -15.1 — — -55.4% —
RARE $2.22B -3.9 20.2% -85.4% -1613.2% —
COAG — — — — — —
KLRA — — — — — —
CDNA $959M -47.1 13.8% -5.6% -6.8% —
PGEN $1.48B -3.1 146.7% -2588.2% 3159.1% —
VERA — -10.9 — — -55.9% —
MLYS $2.96B -15.8 — — -32.2% —

Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie

Compte de résultat 16
Données annuelles Compte de résultat pour BCRX
Métrique Tendance 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +6328.8% $875M $451M $331M $271M $157M $18M $49M $21M $25M $26M $48M $14M
Cost of Revenue 11-point trend, +1907400.0% $19M $12M $4M $6M $7M $2M $4M · $1M $2M $1M $1.0K
R&D Expense 12-point trend, +220.7% $166M $175M $217M $253M $209M $123M $107M $85M $67M $61M $73M $52M
SG&A Expense 12-point trend, +4572.9% $349M $266M $214M $159M $119M $68M $37M $30M $14M $11M $13M $7M
Operating Expenses 12-point trend, +799.1% $534M $453M $435M $419M $335M $193M $148M $115M $83M $75M $88M $59M
Operating Income 12-point trend, +845.0% $341M $-3M $-104M $-148M $-178M $-175M $-99M $-94M $-57M $-49M $-39M $-46M
Interest Expense 10-point trend, +2065.6% · · $108M $99M $59M $15M $12M $9M $9M $6M $5M $5M
Other Non-op 4-point trend, +23.3% $-74M $-84M $-123M $-96M · · · · · · · ·
Pretax Income 7-point trend, +345.5% $267M $-87M $-226M $-244M $-182M $-183M $-109M · · · · ·
Income Tax 11-point trend, +3530000.00 $4M $2M $310.0K $3M $2M $0 $0 $0 $0 $0 $0 ·
Net Income 12-point trend, +683.9% $264M $-89M $-227M $-247M $-184M $-183M $-109M $-101M $-66M $-55M $-43M $-45M
EPS (Basic) 6-point trend, +215.6% $1.26 $-0.43 $-1.18 $-1.33 $-1.03 $-1.09 · · · · · ·
EPS (Diluted) 6-point trend, +211.0% $1.21 $-0.43 $-1.18 $-1.33 $-1.03 $-1.09 · · · · · ·
Shares (Basic) 6-point trend, +25.5% 209,893,000 206,696,000 192,198,000 185,908,000 179,117,000 167,267,000 · · · · · ·
Shares (Diluted) 12-point trend, +227.3% 218,581,000 206,696,000 192,198,000 185,908,000 179,117,000 167,267,000 115,600,000 103,185,000 84,451,000 73,699,000 72,901,000 66,773,000
EBITDA 11-point trend, +850.9% $342M $-1M $-102M $-147M $-177M $-174M $-99M $-93M · $-48M $-39M $-46M
Bilan 27
Données annuelles Bilan pour BCRX
Métrique Tendance 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +64.5% $90M $105M $111M $305M $504M $272M $114M $27M $50M $22M $29M $55M
Short-term Investments 2-point trend, -14.4% $185M $216M · · · · · · · · · ·
Receivables 12-point trend, +2675.2% $107M $79M $57M $51M $29M $9M $22M $4M $6M $9M $6M $4M
Inventory 11-point trend, +690.3% $5M $8M $29M $28M $16M $7M $0 $2M · $500.0K $2M $683.0K
Prepaid Expense 12-point trend, +178.4% $17M $14M $20M $13M $10M $6M $4M $2M $1M $1M $3M $6M
Current Assets 12-point trend, +352.6% $404M $422M $496M $516M $566M $324M $164M $114M $125M $67M $64M $89M
PP&E (Net) 12-point trend, +4143.0% $9M $8M $8M $9M $9M $7M $7M $9M $10M $10M $5M $207.0K
PP&E (Gross) 12-point trend, +27.7% $18M $20M $19M $18M $17M $14M $14M $15M $15M $15M $19M $14M
Accum. Depreciation 12-point trend, -33.0% $9M $12M $11M $10M $8M $7M $7M $6M $5M $5M $14M $14M
Other Non-current Assets 12-point trend, -6.0% $6M $5M $80.0K $7M $6M $4M $4M $978.0K $2M $4M $5M $6M
Total Assets 12-point trend, +275.6% $514M $490M $517M $550M $588M $335M $175M $147M $178M $90M $122M $137M
Accounts Payable 12-point trend, +455.5% $16M $12M $21M $14M $28M $19M $14M $8M $6M $4M $9M $3M
Accrued Liabilities 12-point trend, +1015.8% $126M $113M $103M $88M $73M $34M $21M $16M $13M $11M $16M $11M
Short-term Debt 7-point trend, +0.0% · · · · · $30M $30M $29M $29M $28M $28M $30M
Current Liabilities 12-point trend, +242.2% $196M $160M $150M $106M $104M $106M $92M $69M $75M $54M $62M $57M
Capital Leases 6-point trend, +121.4% $9M $8M $8M $4M $6M $4M · · · · · ·
Other Non-current Liabilities · · · · · · · $3M · · · ·
Total Liabilities 3-point trend, -34.9% $633M $966M $972M · · · · · · · · ·
Long-term Debt 6-point trend, +1196.3% · · · · $298M $123M $50M $30M $23M $23M · ·
Total Debt 11-point trend, -100.0% $0 $315M $303M $232M $136M $150M $30M $29M · $28M $30M $30M
Common Stock 12-point trend, +196.0% $2M $2M $2M $2M $2M $2M $2M $1M $984.0K $738.0K $734.0K $720.0K
Paid-in Capital 12-point trend, +155.1% $1.38B $1.29B $1.22B $1.16B $1.10B $1.00B $877M $780M $715M $567M $558M $543M
Retained Earnings 12-point trend, -221.9% $-1.51B $-1.77B $-1.68B $-1.45B $-1.21B $-1.02B $-841M $-732M $-632M $-566M $-511M $-468M
AOCI 12-point trend, +129.2% $38.0K $921.0K $1M $26.0K $177.0K $3.0K $39.0K $-297.0K $-243.0K $-12.0K $-206.0K $-130.0K
Stockholders' Equity 12-point trend, -257.5% $-119M $-476M $-456M $-295M $-107M $-19M $38M $49M $84M $2M $48M $76M
Liabilities + Equity 12-point trend, +275.6% $514M $490M $517M $550M $588M $335M $175M $147M $178M $90M $122M $137M
Shares Outstanding 12-point trend, +196.1% 213,060,000 208,543,000 205,771,000 187,906,000 184,350,000 176,883,000 154,082,000 110,063,000 98,411,000 73,782,000 73,355,000 71,955,000
Flux de trésorerie 16
Données annuelles Flux de trésorerie pour BCRX
Métrique Tendance 202520242023202220212020201920182017201620152014
D&A 12-point trend, +684.7% $1M $1M $2M $1M $777.0K $748.0K $724.0K $770.0K $704.0K $483.0K $180.0K $177.0K
Stock-based Comp 12-point trend, +735.9% $85M $65M $56M $45M $35M $15M $18M $9M $13M $8M $10M $10M
Deferred Tax 5-point trend, -662.3% $-1M $-354.0K $-682.0K $11.0K $-159.0K · · · · · · ·
Other Non-cash 11-point trend, +53.3% $-2M $-29M $75M $39M $6M $30M $870.0K $-1M · $-7M $20M $-4M
Operating Cash Flow 12-point trend, +1001.1% $347M $-52M $-95M $-162M $-142M $-135M $-90M $-93M $-41M $-53M $-13M $-39M
CapEx 12-point trend, +2228.3% $2M $1M $2M $1M $2M $514.0K $343.0K $366.0K $328.0K $5M $5M $106.0K
Investing Cash Flow 11-point trend, +23.9% $-14M $53M $-131M $-128M $16M $-7M $78M $5M $-65M $23M $-18M ·
Debt Issued 5-point trend, +0.00 $0 $0 $300M $73M $0 · · · · · · ·
Net Debt Issued 3-point trend, -200.0% $-300M $0 $300M · · · · · · · · ·
Stock Issued 8-point trend, -100.0% · · $0 $0 $50M $93M $58M $53M $134M · · $107M
Net Stock Activity 7-point trend, -100.0% · · $0 $0 $50M $93M $58M $53M · · · $107M
Financing Cash Flow 11-point trend, -6486.8% $-350M $-6M $32M $88M $360M $301M $99M $63M $136M $23M $5M ·
Net Change in Cash 12-point trend, -144.9% $-15M $-6M $-194M $-201M $233M $159M $87M $-25M $30M $-7M $-26M $33M
Taxes Paid 3-point trend, +95.5% $3M $2M $1M · · · · · · · · ·
Free Cash Flow 11-point trend, +992.2% $345M $-53M $-97M $-163M $-145M $-138M $-90M $-93M · $-59M $-18M $-39M
Levered FCF 4-point trend, -35.1% · · $-206M $-263M $-205M $-152M · · · · · ·
Rentabilité 7
Données annuelles Rentabilité pour BCRX
Métrique Tendance 202520242023202220212020201920182017201620152014
Operating Margin 11-point trend, +111.6% 39.0% -0.56% -31.3% -54.8% -113.1% -981.1% -203.7% -456.2% · -184.4% -81.7% -336.4%
Net Margin 11-point trend, +109.1% 30.2% -19.7% -68.4% -91.2% -117.1% -1026.4% -223.0% -490.2% · -209.2% -89.1% -332.1%
Pretax Margin 6-point trend, +103.0% 30.6% -19.3% -68.3% -90.2% -115.7% -1026.4% · · · · · ·
EBITDA Margin 11-point trend, +111.7% 39.1% -0.29% -30.8% -54.3% -112.6% -976.9% -202.2% -452.5% · -182.6% -81.4% -335.0%
ROA 11-point trend, +208.0% 52.5% -17.6% -42.5% -43.4% -39.9% -71.7% -67.6% -62.3% · -52.0% -32.9% -48.7%
ROE 11-point trend, +19.5% -97.6% 18.8% 52.3% 92.0% 144.9% -2543.5% 7257.4% -165.8% · -223.7% -69.8% -121.3%
ROIC 6-point trend, -110.8% -282.4% 1.6% 68.2% 238.4% -618.4% -133.9% · · · · · ·
Liquidité et Solvabilité 5
Données annuelles Liquidité et Solvabilité pour BCRX
Métrique Tendance 202520242023202220212020201920182017201620152014
Current Ratio 11-point trend, +33.2% 2.1 2.6 3.3 4.9 5.5 3.1 1.8 1.6 · 1.2 1.0 1.5
Quick Ratio 11-point trend, +105.8% 1.9 1.1 1.1 3.4 5.1 2.7 1.5 0.4 · 0.6 0.5 0.9
Debt / Equity 11-point trend, -100.0% 0.0 -0.7 -0.7 -0.8 -1.3 -7.8 0.8 0.6 · 17.9 0.6 0.4
LT Debt / Equity 6-point trend, +100.0% 0.0 -0.7 -0.7 -0.8 -1.3 -6.2 · · · · · ·
Interest Coverage 9-point trend, +89.5% · · -1.0 -1.5 -3.0 -12.1 -8.4 -10.3 · -7.5 -7.6 -9.2
Efficacité 3
Données annuelles Efficacité pour BCRX
Métrique Tendance 202520242023202220212020201920182017201620152014
Asset Turnover 11-point trend, +1088.9% 1.7 0.9 0.6 0.5 0.3 0.1 0.3 0.1 · 0.2 0.4 0.1
Inventory Turnover 9-point trend, +97455.2% 2.8 0.4 0.2 0.3 0.6 0.4 · · · 2.2 1.2 0.0
Receivables Turnover 10-point trend, -1.6% 9.4 6.6 6.2 6.8 8.3 1.2 3.7 4.0 · 3.5 9.6 ·
Par action 5
Données annuelles Par action pour BCRX
Métrique Tendance 202520242023202220212020201920182017201620152014
Book Value / Share 11-point trend, -153.2% $-0.56 $-2.28 $-2.21 $-1.57 $-0.58 $-0.11 $0.25 $0.45 · $0.02 $0.65 $1.05
Revenue / Share 10-point trend, +504.6% $4.00 $2.18 $1.72 $1.46 $0.88 $0.11 $0.42 $0.20 · $0.36 $0.66 ·
Cash Flow / Share 10-point trend, +983.4% $1.59 $-0.25 $-0.49 $-0.87 $-0.79 $-0.82 $-0.77 $-0.90 · $-0.73 $-0.18 ·
Cash / Share 11-point trend, -44.4% $0.42 $0.50 $0.54 $1.62 $2.74 $1.54 $0.74 $0.24 · $0.30 $0.39 $0.76
EPS (TTM) 11-point trend, +301.7% $1.21 $-0.43 $-1.18 $-1.33 $-1.03 $-1.09 $-0.61 $-0.61 $-0.61 $-0.61 $-0.60 ·
Taux de croissance 3
Données annuelles Taux de croissance pour BCRX
Métrique Tendance 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, -88.0% 94.1% 36.0% 22.4% 72.3% 782.4% · · · · · · ·
Revenue CAGR 3Y 3-point trend, -71.0% 47.8% 42.1% 165.0% · · · · · · · · ·
Revenue CAGR 5Y 117.9% · · · · · · · · · · ·
Valorisation (TTM) 13
Données annuelles Valorisation (TTM) pour BCRX
Métrique Tendance 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +6328.8% $875M $451M $331M $271M $157M $18M $49M $21M $25M $26M $48M $14M
Net Income TTM 12-point trend, +683.9% $264M $-89M $-227M $-247M $-184M $-183M $-109M $-101M $-66M $-55M $-43M $-45M
Market Cap 11-point trend, +89.9% $1.66B $1.57B $1.23B $2.16B $2.55B $1.32B $532M $888M · $467M $757M $875M
Enterprise Value 11-point trend, +63.1% $1.39B $1.78B $1.43B $2.08B $2.18B $1.20B $447M $891M · $473M $758M $850M
P/E 11-point trend, +137.5% 6.4 -17.5 -5.1 -8.6 -13.4 -6.8 -5.7 -13.2 -8.0 -10.4 -17.2 ·
P/S 11-point trend, -97.0% 1.9 3.5 3.7 8.0 16.2 74.0 10.9 43.0 · 17.7 15.7 64.3
P/B 11-point trend, -220.6% -13.9 -3.3 -2.7 -7.3 -23.9 -68.4 13.9 18.0 · 296.0 15.9 11.6
P / Cash Flow 11-point trend, +121.1% 4.8 -30.1 -13.0 -13.3 -18.0 -9.6 -5.9 -9.6 · -8.7 -57.7 -22.7
P / FCF 11-point trend, +121.3% 4.8 -29.5 -12.7 -13.2 -17.7 -9.6 -5.9 -9.6 · -8.0 -41.5 -22.6
EV / EBITDA 11-point trend, +121.7% 4.1 -1371.2 -14.0 -14.2 -12.3 -6.9 -4.5 -9.5 · -9.8 -19.3 -18.7
EV / FCF 11-point trend, +118.3% 4.0 -33.5 -14.6 -12.8 -15.1 -8.7 -5.0 -9.6 · -8.1 -41.6 -22.0
EV / Revenue 11-point trend, -97.5% 1.6 3.9 4.3 7.7 13.9 67.1 9.2 43.1 · 18.0 15.7 62.5
Earnings Yield 11-point trend, +367.0% 15.5% -5.7% -19.7% -11.6% -7.4% -14.6% -17.7% -7.6% -12.4% -9.6% -5.8% ·

États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années

Compte de résultat
2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenu $875M$451M$331M$271M$157M
Marge d'exploitation % 39.0%-0.56%-31.3%-54.8%-113.1%
Résultat net $264M$-89M$-227M$-247M$-184M
BPA dilué $1.21$-0.43$-1.18$-1.33$-1.03
Bilan
2025-12-312024-12-312023-12-312022-12-312021-12-31
Dette / Capitaux propres 0.0-0.7-0.7-0.8-1.3
Ratio de liquidité 2.12.63.34.95.5
Ratio de liquidité réduite 1.91.11.13.45.1
Flux de trésorerie
2025-12-312024-12-312023-12-312022-12-312021-12-31
Flux de trésorerie libre $345M$-53M$-97M$-163M$-145M

Dernières actualités Actualités récentes mentionnant cette entreprise

Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets

📊

Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.

Votre sélection est enregistrée et vous suit sur tous les tickers.

Détenteurs institutionnels (13F) 346 déclarants · $2.1B total · Au 30 juin 2026

Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.

Activité institutionnelle — Q2 2026 vs trimestre précédent
Nouvelles positions Positions clôturées Augmenté Diminué Variation nette des actions
63 (-7 vs T. préc.) 34 (-7 vs T. préc.) 130 (+19 vs T. préc.) 83 (+3 vs T. préc.) +25.9M

Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.

Institution Valeur Actions % de 13F suivies Type
RA CAPITAL MANAGEMENT, L.P. $158 271 860 15 827 186 7,51% Actions
STATE STREET CORP $151 910 980 15 191 098 7,21% Actions
DEERFIELD MANAGEMENT COMPANY, L.P. $150 964 030 15 096 403 7,16% Actions
VANGUARD CAPITAL MANAGEMENT LLC $113 642 360 11 364 236 5,39% Actions
VANGUARD PORTFOLIO MANAGEMENT LLC $111 391 580 11 139 158 5,29% Actions
TCG Crossover Management, LLC $110 209 680 11 020 968 5,23% Actions
PERCEPTIVE ADVISORS LLC $103 088 880 10 308 888 4,89% Actions
JANUS HENDERSON GROUP PLC $83 961 589 8 814 865 3,98% Actions
Vestal Point Capital, LP $83 000 000 8 300 000 3,94% Actions
TWO SIGMA INVESTMENTS, LP $67 753 490 6 775 349 3,21% Actions
GEODE CAPITAL MANAGEMENT, LLC $53 581 572 5 356 880 2,54% Actions
Aberdeen Group plc $53 108 710 5 310 871 2,52% Actions
Frazier Life Sciences Management, L.P. $40 092 400 4 009 240 1,90% Actions
GOLDMAN SACHS GROUP INC $35 393 210 3 539 321 1,68% Actions
MILLENNIUM MANAGEMENT LLC $33 947 290 3 394 729 1,61% Actions
TWO SIGMA ADVISERS, LP $31 895 074 4 089 112 1,51% Actions
RP Management, LLC $28 846 155 3 846 154 1,37% Actions
DIMENSIONAL FUND ADVISORS LP $27 161 110 2 716 111 1,29% Actions
Fisher Asset Management, LLC $26 040 270 2 604 027 1,24% Actions
RENAISSANCE TECHNOLOGIES LLC $25 302 900 2 530 290 1,20% Actions
Kynam Capital Management, LP $25 226 600 2 522 660 1,20% Actions
Candriam S.C.A. $25 125 293 2 514 949 1,19% Actions
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $23 532 910 2 353 291 1,12% Actions
RICE HALL JAMES & ASSOCIATES, LLC $23 320 430 2 332 043 1,11% Actions
AQR CAPITAL MANAGEMENT LLC $21 850 110 2 185 011 1,04% Actions
Nantahala Capital Management, LLC $19 011 600 1 901 160 0,90% Actions
Eversept Partners, LP $18 656 530 1 865 653 0,89% Actions
ORBIMED ADVISORS LLC $18 520 000 1 852 000 0,88% Actions
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND $18 449 120 1 844 912 0,88% Actions
VANGUARD FIDUCIARY TRUST CO $17 595 730 1 759 573 0,83% Actions
CITADEL ADVISORS LLC $17 591 600 1 759 160 0,83% Actions
IMC-Chicago, LLC $16 343 360 1 634 336 0,78% Actions
Parkman Healthcare Partners LLC $16 242 790 1 624 279 0,77% Actions
JANE STREET GROUP, LLC $14 267 680 1 426 768 0,68% Actions
OP Asset Management Ltd $13 409 900 1 340 990 0,64% Actions
SUSQUEHANNA INTERNATIONAL GROUP, LLP $11 956 510 1 195 651 0,57% Actions
Pictet Asset Management Holding SA $11 951 392 1 249 771 0,57% Actions
BNP PARIBAS FINANCIAL MARKETS $11 740 520 1 174 052 0,56% Actions
FIRST TRUST ADVISORS LP $11 204 690 1 120 469 0,53% Actions
JANE STREET GROUP, LLC $9 944 130 994 413 0,47% Option d'achat
Cubist Systematic Strategies, LLC $9 462 419 1 246 696 0,45% Actions
MOORE CAPITAL MANAGEMENT, LP $8 483 360 848 336 0,40% Actions
FMR LLC $8 062 330 806 233 0,38% Actions
BANK OF AMERICA CORP /DE/ $7 754 020 775 402 0,37% Actions
ExodusPoint Capital Management, LP $7 449 170 744 917 0,35% Actions
Man Group plc $7 324 800 732 480 0,35% Actions
Rosalind Advisors, Inc. $7 215 040 721 504 0,34% Actions
Schonfeld Strategic Advisors LLC $7 108 160 710 816 0,34% Actions
BlackRock, Inc. $5 984 400 598 440 0,28% Actions
Elmind Capital, LP $5 200 000 520 000 0,25% Actions
Bridgewater Associates, LP $4 910 570 491 057 0,23% Actions
NAN FUNG TRINITY (HK) LTD $4 500 000 450 000 0,21% Actions
SPHERA FUNDS MANAGEMENT LTD. $4 220 510 422 051 0,20% Actions
Swiss National Bank $4 152 680 415 268 0,20% Actions
Susquehanna Portfolio Strategies, LLC $4 047 040 404 704 0,19% Actions
DAFNA Capital Management LLC $4 002 480 400 248 0,19% Actions
Hudson Bay Capital Management LP $4 000 000 400 000 0,19% Actions
Aquatic Capital Management LLC $3 628 950 362 895 0,17% Actions
DOLIVER CAPITAL ADVISORS, INC. $3 563 603 374 328 0,17% Actions
Assenagon Asset Management S.A. $3 530 440 353 044 0,17% Actions
Kodai Capital Management LP $3 515 993 468 799 0,17% Actions
MACKENZIE FINANCIAL CORP $3 472 990 347 299 0,16% Actions
CITIGROUP INC $3 467 520 346 752 0,16% Actions
Phocas Financial Corp. $3 405 410 340 541 0,16% Actions
SUSQUEHANNA INTERNATIONAL GROUP, LLP $3 238 000 323 800 0,15% Option d'achat
ALPS ADVISORS INC $3 179 600 317 960 0,15% Actions
ALLIANCEBERNSTEIN L.P. $3 121 694 327 909 0,15% Actions
RHUMBLINE ADVISERS $2 798 390 279 839 0,13% Actions
Rafferty Asset Management, LLC $2 656 180 265 618 0,13% Actions
Point72 Asset Management, L.P. $2 609 170 260 917 0,12% Actions
Nuveen, LLC $2 599 030 259 903 0,12% Actions
NFJ INVESTMENT GROUP, LLC $2 568 330 256 833 0,12% Actions
Nebula Research & Development LLC $2 567 121 286 509 0,12% Actions
WINTON GROUP Ltd $2 556 000 255 600 0,12% Actions
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $2 459 444 258 345 0,12% Actions
MARTINGALE ASSET MANAGEMENT L P $2 425 080 242 508 0,12% Actions
WELLINGTON MANAGEMENT GROUP LLP $2 324 670 232 467 0,11% Actions
CITADEL ADVISORS LLC $2 322 000 232 200 0,11% Option d'achat
IEQ CAPITAL, LLC $2 274 210 227 421 0,11% Actions
Bank of New York Mellon Corp $2 251 670 225 167 0,11% Actions
D. E. Shaw & Co., Inc. $2 249 120 224 912 0,11% Actions
JUPITER ASSET MANAGEMENT LTD $2 221 030 222 103 0,11% Actions
HUSSMAN STRATEGIC ADVISORS, INC. $2 100 000 210 000 0,10% Actions
PFM Health Sciences, LP $2 073 570 207 357 0,10% Actions
VANGUARD ASSET MANAGEMENT, Ltd $1 962 800 196 280 0,09% Actions
TUDOR INVESTMENT CORP ET AL $1 951 280 195 128 0,09% Actions
SUSQUEHANNA INTERNATIONAL GROUP, LLP $1 853 000 185 300 0,09% Option de vente
VIRGINIA RETIREMENT SYSTEMS ET Al $1 820 161 233 354 0,09% Actions
Engineers Gate Manager LP $1 750 020 175 002 0,08% Actions
Squarepoint Ops LLC $1 747 140 174 714 0,08% Actions
QTR Family Wealth, LLC $1 610 820 161 082 0,08% Actions
Gotham Asset Management, LLC $1 564 210 156 421 0,07% Actions
CITADEL ADVISORS LLC $1 450 000 145 000 0,07% Option de vente
Corient Private Wealth LP $1 429 860 142 986 0,07% Actions
NEW YORK STATE COMMON RETIREMENT FUND $1 386 570 138 657 0,07% Actions
Quantinno Capital Management LP $1 374 530 137 453 0,07% Actions
MetLife Investment Management, LLC $1 356 700 135 670 0,06% Actions
PROFUND ADVISORS LLC $1 340 340 134 034 0,06% Actions
Virtus Investment Advisers, LLC $1 336 640 133 664 0,06% Actions
ADAR1 Capital Management, LLC $1 330 000 133 000 0,06% Actions

Initiés de la société 51 initiés · 21 dirigeants · 30 administrateurs

Dirigeant Rôle Dernière activité Actions détenues Achats 12m Ventes 12m Net 12m
Babar Ghias Chief Financial Officer 17 décembre 2025 A 268 700 0 0 $0
Anthony Doyle Chief Financial Officer 19 décembre 2024 A 377 867 0 0 $0
Thomas R Staab II Senior Vice President and CFO 21 février 2020 A 125 176 0 0 $0
Stuart Grant SR VP & CFO 16 mars 2011 M 57 102 0 0 $0
Charles K Gayer President and CCO 22 décembre 2025 M 952 583 0 0 $0
Claude J Bennett Chief Operating Officer 14 mars 2008 A 65 730 0 0 $0
Alane P Barnes Chief Legal Officer 13 mai 2026 M 400 703 0 7 $-3 461 969
Sandeep Menon Chief R&D Officer 6 avril 2026 A 205 150 0 0 $0
Helen M. Thackray Chief R&D Officer 31 mars 2025 F 377 318 0 0 $0
Michael L Jones Exec. Director, Finance - PAO 19 décembre 2022 A 16 653 0 0 $0
Yarlagadda S Babu Chief Discovery Officer 14 novembre 2022 M 298 541 0 0 $0
William P Sheridan Chief Medical Officer 10 mars 2022 M 37 954 0 0 $0
Megan Sniecinski Chief Business Officer 15 décembre 2020 A 45 000 0 0 $0
Lynne Powell Senior VP - CCO 28 janvier 2019 M 0 0 0 $0
David Mccullough VP 15 mars 2012 F 24 124 0 0 $0
Robert S Lowrey Controller, PAO 7 février 2011 A 9 766 0 0 $0
Mike Mills Principal Accounting Officer 12 mars 2010 M 0 0 0 $0
Michael A Darwin Principal Accounting Officer 31 juillet 2008 P 3 048 0 0 $0
Jonathan M Nugent VP Corp Communications 31 juillet 2007 P 508 0 0 $0
James W Alexander SR. VP, Chief Medical Officer 31 juillet 2007 P 3 659 0 0 $0
Randall B Riggs Senior VP Business Development 16 mai 2007 A 1 928 0 0 $0
Amy E Mckee Administrateur 11 juin 2026 A 47 177 0 1 $-100 285
Theresa Heggie Administrateur 11 juin 2026 A 80 646 0 1 $-504 823
Machelle Sanders Administrateur 11 juin 2026 A 45 936 0 1 $-68 544
Jill C. Milne Administrateur 11 juin 2026 A 31 938 0 0 $0
Steven Frank Administrateur 11 juin 2026 A 35 459 0 0 $0
Steven K Galson Administrateur 11 juin 2026 A 27 794 0 0 $0
Jon P Stonehouse Administrateur 11 juin 2026 A 1 339 775 0 0 $0
Vincent Milano Administrateur 11 juin 2026 A 108 483 0 0 $0
Alan G Levin Administrateur 11 juin 2026 A 79 565 0 0 $0
Nancy J Hutson Administrateur 12 juin 2025 A 99 138 0 0 $0
George B Abercrombie Administrateur 12 juin 2024 A 36 431 0 0 $0
Steve Aselage Administrateur 12 juin 2024 A 70 159 0 0 $0
Kenneth B Lee JR Administrateur 13 juin 2023 A 68 863 0 0 $0
Robert Alexander Ingram Administrateur 28 février 2023 A 100 198 0 0 $0
Stanley C Erck Administrateur 28 novembre 2018 M 48 333 0 0 $0
Fred Cohen Administrateur 20 juin 2018 A 119 410 0 0 $0
Sanj K Patel Administrateur 24 mai 2017 A — 0 0 $0
Charles A Sanders Administrateur 29 février 2016 A 12 971 0 0 $0
Peder Jensen Administrateur 2 mai 2014 A 60 000 0 0 $0
John L Higgins Administrateur 23 mai 2012 A — 0 0 $0
HOROVITZ ZOLA P Administrateur 23 mai 2012 A 3 000 0 0 $0
Stephen R Biggar Administrateur 12 mai 2011 A — 0 0 $0
Beth C Seidenberg Administrateur 13 mai 2010 A 3 000 0 0 $0
William W Featheringill Administrateur 13 mai 2010 A 231 538 0 0 $0
William M Spencer III Administrateur 16 mai 2007 A 186 761 0 0 $0
Joseph H Sherrill JR Administrateur 16 mai 2007 A 451 900 0 0 $0
Charles E Bugg Administrateur 18 mars 2007 A 62 439 0 0 $0
GORDON CARL L Administrateur 17 mai 2006 A 1 100 000 0 0 $0
John A Montgomery Administrateur 4 novembre 2003 M 46 785 0 0 $0

Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché

Activistes et détenteurs de 5%+ 15 participations

Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.

Déclarant Déposé Participation Statut Objectif Dépôt
Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 dépôts 31 juillet 2018 — Dépôt initial — SEC
RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. 2 avril 2018 — Dépôt initial Investissement passif SEC
Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 dépôts 16 août 2016 — Dépôt initial — SEC
Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 dépôts 23 octobre 2012 — Dépôt initial — SEC
Julian C. Baker, Felix J. Baker ×4 dépôts 13 octobre 2011 — Dépôt initial — SEC
L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 dépôts 20 août 2007 — Dépôt initial — SEC
Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée 7 décembre 2005 — Dépôt initial — SEC
Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée 7 décembre 2005 — Dépôt initial — SEC
Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée 7 décembre 2005 — Dépôt initial — SEC
Personne déclarante non divulguée 13 octobre 2005 — Dépôt initial — SEC
Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée 26 février 2004 — Dépôt initial — SEC
Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée 25 février 2004 — Dépôt initial — SEC
Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée 24 février 2004 — Dépôt initial — SEC
Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 dépôts 31 octobre 2003 — Dépôt initial — SEC
William W. Featheringill 14 février 2002 — Dépôt initial — SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Détention d'ETF Détenu par 53 ETFs

Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.

Fonds Poids Unités Au Source
PBE · Invesco Exchange-Traded Fund Trust 2,65% 1 023 838 SH 8 août 2026 Quotidien
BBP · ETFis Series Trust I 1,93% 125 015 NS 30 avril 2026 N-PORT
ABLS · Abacus FCF ETF Trust 1,26% 1 682 NS 30 avril 2026 N-PORT
LABU · Direxion Shares ETF Trust 0,67% 381 305 NS 30 avril 2026 N-PORT
FYC · First Trust Exchange-Traded AlphaDE… 0,54% 612 341 NS 30 avril 2026 N-PORT
CALF · Pacer Funds Trust 0,41% 1 556 494 NS 30 avril 2026 N-PORT
FYX · First Trust Exchange-Traded AlphaDE… 0,28% 364 624 NS 30 avril 2026 N-PORT
BFOR · ALPS ETF Trust 0,25% 59 894 NS 31 mai 2026 N-PORT
OMFS · Invesco Exchange-Traded Self-Indexe… 0,24% 72 535 SH 8 août 2026 Quotidien
GSSC · Goldman Sachs ETF Trust 0,19% 213 133 NS 31 mai 2026 N-PORT
SMLF · iShares Trust 0,17% 758 958 SH 8 août 2026 Quotidien
IBBQ · Invesco Exchange-Traded Fund Trust … 0,16% 13 830 SH 8 août 2026 Quotidien
IBB · iShares Trust 0,15% 1 580 105 SH 8 août 2026 Quotidien
ESSC · Strategy Shares 0,15% 4 183 NS 30 avril 2026 N-PORT
VTWG · VANGUARD SCOTTSDALE FUNDS 0,14% 249 665 SH 8 août 2026 Quotidien
IWO · iShares Trust 0,13% 2 097 061 SH 8 août 2026 Quotidien
BIB · ProShares Trust 0,11% 9 271 NS 31 mai 2026 N-PORT
FAD · First Trust Exchange-Traded AlphaDE… 0,11% 57 134 NS 30 avril 2026 N-PORT
BBSC · J.P. Morgan Exchange-Traded Fund Tr… 0,10% 81 871 NS 30 avril 2026 N-PORT
VTWO · VANGUARD SCOTTSDALE FUNDS 0,07% 1 339 774 SH 8 août 2026 Quotidien
ISCG · iShares Trust 0,07% 73 787 SH 8 août 2026 Quotidien
IWM · iShares Trust 0,07% 5 925 076 SH 8 août 2026 Quotidien
PRFZ · Invesco Exchange-Traded Fund Trust 0,07% 206 325 SH 8 août 2026 Quotidien
RSSL · Global X Funds 0,06% 97 958 NS 30 avril 2026 N-PORT
DFAS · Dimensional ETF Trust 0,05% 806 097 NS 30 avril 2026 N-PORT
ITWO · ProShares Trust 0,05% 10 652 NS 31 mai 2026 N-PORT
SCHA · SCHWAB STRATEGIC TRUST 0,05% 1 154 262 NS 31 mai 2026 N-PORT
VBK · VANGUARD INDEX FUNDS 0,04% 1 696 014 SH 8 août 2026 Quotidien
ISCB · iShares Trust 0,03% 10 494 SH 8 août 2026 Quotidien
FHLC · FIDELITY COVINGTON TRUST 0,03% 96 151 NS 30 avril 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0,03% 2 837 341 SH 8 août 2026 Quotidien
VHT · VANGUARD WORLD FUND 0,03% 624 412 SH 8 août 2026 Quotidien
UWM · ProShares Trust 0,03% 8 331 NS 31 mai 2026 N-PORT
URTY · ProShares Trust 0,02% 8 425 NS 31 mai 2026 N-PORT
VB · VANGUARD INDEX FUNDS 0,02% 2 922 024 SH 8 août 2026 Quotidien
WSML · iShares Trust 0,02% 11 689 SH 8 août 2026 Quotidien
MSSM · MORGAN STANLEY PATHWAY FUNDS 0,01% 9 529 NS 31 mai 2026 N-PORT
HDG · ProShares Trust 0,01% 212 NS 31 mai 2026 N-PORT
ONEQ · Fidelity Commonwealth Trust 0,01% 80 493 NS 31 mai 2026 N-PORT
DFUS · Dimensional ETF Trust 0,00% 74 317 NS 30 avril 2026 N-PORT
IWV · iShares Trust 0,00% 72 218 SH 8 août 2026 Quotidien
AVUQ · AMERICAN CENTURY ETF TRUST 0,00% 937 NS 31 mai 2026 N-PORT
ITOT · iShares Trust 0,00% 336 352 SH 8 août 2026 Quotidien
SCHB · SCHWAB STRATEGIC TRUST 0,00% 141 645 NS 31 mai 2026 N-PORT
TILT · FlexShares Trust 0,00% 6 314 NS 30 avril 2026 N-PORT
DFAC · Dimensional ETF Trust 0,00% 34 873 NS 30 avril 2026 N-PORT
DFAT · Dimensional ETF Trust 0,00% 8 956 NS 30 avril 2026 N-PORT
FSCC · Federated Hermes ETF Trust 0,00% 129 NS 31 mai 2026 N-PORT
DFAU · Dimensional ETF Trust 0,00% 3 019 NS 30 avril 2026 N-PORT
VTI · VANGUARD INDEX FUNDS 0,00% 8 070 274 SH 8 août 2026 Quotidien